Pridopidine activates neuroprotective pathways impaired in Huntington Disease

Human Molecular Genetics

Volumn 25, Issue 18, 2016, Pages 3975-3987

  Geva, Michal ^a   Kusko, Rebecca ^b   Soares, Holly ^a   Fowler, Kevin D ^b   Birnberg, Tal ^a   Barash, Steve ^a   Merenlender Wagner, Avia ^a   Fine, Tania ^a   Lysaght, Andrew ^b   Weiner, Brian ^b   Cha, Yoonjeong ^b   Kolitz, Sarah ^b   Towfic, Fadi ^b   Orbach, Aric ^a   Laufer, Ralph ^a   Zeskind, Ben ^b   Grossman, Iris ^a   Hayden, Michael R ^a  

^a TEVA PHARMACEUTICALS   (Israel)

^b Immuneering Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DEXAMETHASONE; DOPAMINE 1 RECEPTOR; DUAL SPECIFICITY PHOSPHATASE; DUAL SPECIFICITY PHOSPHATASE 14; DUAL SPECIFICITY PHOSPHATASE 6; EARLY GROWTH RESPONSE FACTOR 1; EARLY GROWTH RESPONSE FACTOR 2; GLUCOCORTICOID RECEPTOR; KRUPPEL LIKE FACTOR 5; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; NEUROPROTECTIVE AGENT; NUCLEAR RECEPTOR NUR77; PER1 PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PRIDOPIDINE; PROTEIN FOS; PROTEIN HOMER 1A; PROTEIN KINASE B; PYRUVATE DEHYDROGENASE KINASE 4; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; SIGMA 1 OPIATE RECEPTOR; UNCLASSIFIED DRUG; DOPAMINE 5 RECEPTOR; PIPERIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; DOWN REGULATION; DRUG MECHANISM; GENE EXPRESSION PROFILING; GENOME-WIDE ASSOCIATION STUDY; HUNTINGTON CHOREA; IN VIVO STUDY; LONG TERM CARE; MALE; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; REPEATED DRUG DOSE; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GENOME; HUMAN; HUNTINGTON DISEASE; METABOLISM; MOUSE; PATHOLOGY;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GENOME; HUMANS; HUNTINGTON DISEASE; MICE; NEUROPROTECTIVE AGENTS; PIPERIDINES; RATS; RECEPTORS, DOPAMINE D5; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION;

EID: 84995734018     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddw238     Document Type: Article

References (58)

1. Bertram, L. and Tanzi, R.E. (2005) The genetic epidemiology of neurodegenerative disease. J. Clin. Invest., 115, 1449-1457.
2. Fisher, E.R. and Hayden, M.R. (2014) Multisource ascertainment of Huntington disease in Canada: Prevalence and population at risk: Multisource Ascertainment of BC HD Patients. Mo.T Disord., 29, 105-114.
3. Dyhring, T., Nielsen, E., Sonesson, C., Pettersson, F., Karlsson, J., Svensson, P., Christophersen, P. and Waters, N. (2010) The dopaminergic stabilizers pridopidine (ACR16) and (+)-OSU6162 display dopamine D2 receptor antagonism and fast receptor dissociation properties. Eur. J. Pharmacol., 628, 19-26.
4. de Yebenes, J.G., Landwehrmeyer, B., Squitieri, F., Reilmann, R., Rosser, A., Barker, R.A., Saft, C., Magnet, M.K., Sword, A., Rembratt, Å., et al. (2011) Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebocontrolled trial. Lancet. Neurol., 10, 1049-1057.
5. Huntington Study Group HART Investigators (2013) A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease. Mov. Disord., 28, 1407-1415.
6. Sahlholm, K., Å rhem, P., Fuxe, K. and Marcellino, D. (2013) The dopamine stabilizers ACR16 and (+)-OSU6162 display nanomolar affinities at the r-1 receptor. Mol. Psychiatry, 18, 12-14.
7. Sahlholm, K., Sijbesma, J.W.A., Maas, B., Kwizera, C., Marcellino, D., Ramakrishnan, N.K., Dierckx, R.A.J.O., Elsinga, P.H. and van Waarde, A. (2015) Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses. Psychopharmacology (Berl.), 232, 3443-3453.
8. Ishikawa, M. and Hashimoto, K. (2010) The role of sigma-1 receptors in the pathophysiology of neuropsychiatric diseases. J. Rec. Lig. Chan., 3, 25-36.
9. Miki, Y., Tanji, K., Mori, F. and Wakabayashi, K. (2015) Sigma-1 receptor is involved in degradation of intranuclear inclusions in a cellular model of Huntington's disease. Neurobiol. Dis., 74, 25-31.
10. Al-Saif, A., Al-Mohanna, F. and Bohlega, S. (2011) A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. Ann. Neurol., 70, 913-919.
11. Luty, A.A., Kwok, J.B.J., Dobson-Stone, C., Loy, C.T., Coupland, K.G., Karlström, H., Sobow, T., Tchorzewska, J., Maruszak, A., Barcikowska, M., et al. (2010) Sigma nonopioid intracellular receptor 1mutations cause frontotemporal lobar degenerationmotor neuron disease. Ann. Neurol., 68, 639-649.
12. Fehér, Á., Juhász, A., László, A., Kálmán, J., Pákáski, M., Kálmán, J. and Janka, Z. (2012) Association between a variant of the sigma-1 receptor gene and Alzheimer's disease. Neurosci. Lett., 517, 136-139.
13. Miyatake, R., Furukawa, A., Matsushita, S., Higuchi, S. and Suwaki, H. (2004) Functional polymorphisms in the sigma1 receptor gene associatedwith alcoholism. Biol. Psychiatry, 55, 85-90.
14. Uchida, N., Ujike, H., Tanaka, Y., Sakai, A., Yamamoto, M., Fujisawa, Y., Kanzaki, A. and Kuroda, S. (2005) A variant of the sigma receptor type-1 gene is a protective factor for Alzheimer disease. Am. J. Geriatr. Psychiatry, 13, 1062-1066.
15. Huang, Y., Zheng, L., Halliday, G., Dobson-Stone, C., Wang, Y., Tang, H.D., Cao, L., Deng, Y.L., Wang, G., Zhang, Y.M., et al. (2011) Genetic polymorphisms in sigma-1 receptor and apolipoprotein E interact to influence the severity of Alzheimer's disease. Curr. Alzheimer. Res., 8, 765-770.
16. Calella, A.M., Nerlov, C., Lopez, R.G., Sciarretta, C., von Bohlen und Halbach, O., Bereshchenko, O. and Minichiello, L. (2007) Neurotrophin/Trk receptor signaling mediates C/EBPalpha,-beta and NeuroD recruitment to immediate-early gene promoters in neuronal cells and requires C/EBPs to induce immediate-early gene transcription. Neural. Dev, 2, 4.
17. Gokce, O., Runne, H., Kuhn, A. and Luthi-Carter, R. (2009) Short-Term Striatal Gene Expression Responses to Brain-Derived Neurotrophic Factor Are Dependent on MEK and ERK Activation. PLoS ONE, 4, e5292., Date last accessed July 21, 2016.
18. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S. A., 102, 15545-15550.
19. Malik, M., Rangel-Barajas, C., Sumien, N., Su, C., Singh, M., Chen, Z., Huang, R.Q., Meunier, J., Maurice, T., Mach, R.H., et al. (2015) The effects of sigma (r1) receptor-selective ligands on muscarinic receptor antagonist-induced cognitive deficits in mice: Cognitive beneficial effect of the sigma(1) receptor ligand LS-1-137. Brit. J. Pharmacol., 172, 2519-2531.
20. Francardo, V., Bez, F., Wieloch, T., Nissbrandt, H., Ruscher, K. and Cenci, M.A. (2014) Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism. Brain, 137, 1998-2014.
21. Fujimoto, M., Hayashi, T., Urfer, R., Mita, S. and Su, T.P. (2012) Sigma-1 receptor chaperones regulate the secretion of brain-derived neurotrophic factor. Synapse, 66, 630-639.
22. Chao, M.V. (2003) Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat. Rev. Neurosci., 4, 299-309.
23. Cadet, J.L., Jayanthi, S., McCoy, M.T., Beauvais, G. and Cai, N.S. (2010) Dopamine D1 receptors, regulation of gene expression in the brain, and neurodegeneration. CNS Neurol. Disord. Drug Targets, 9, 526-538.
24. Maheshwari, M., Shekhar, S., Singh, B.K., Jamal, I., Vatsa, N., Kumar, V., Sharma, A. and Jana, N.R. (2014) Deficiency of Ube3a in Huntington's disease mice brain increases aggregate load and accelerates disease pathology. Hum. Mol. Genet., 23, 6235-6245.
25. Sato, H., Horikawa, Y., Iizuka, K., Sakurai, N., Tanaka, T., Shihara, N., Oshima, A., Takeda, J. and Mikuni, M. (2008) Large-scale analysis of glucocorticoid target genes in rat hypothalamus. J. Neurochem., 106, 805-814.
26. Walker, F.O. (2007) Huntington's disease. The Lancet, 369, 218-228.
27. Brito, V., Puigdellívol, M., Giralt, A., del Toro, D., Alberch, J. and Ginés, S. (2013) Imbalance of p75NTR/TrkB protein expression in Huntington's disease: implication for neuroprotective therapies. Cell Death Dis., 4, e595., date last accessed July 21, 2016.
28. Xie, Y., Hayden, M.R. and Xu, B. (2010) BDNF Overexpression in the Forebrain Rescues Huntington's Disease Phenotypes in YAC128 Mice. J. Neurosci., 30, 14708-14718.
29. Zuccato, C. and Cattaneo, E. (2007) Role of brain-derived neurotrophic factor in Huntington's disease. Prog. Neurobiol., 81, 294-330.
30. Franke, T.F., Hornik, C.P., Segev, L., Shostak, G.A. and Sugimoto, C. (2003) PI3K/Akt and apoptosis: size matters. Oncogene, 22, 8983-8998.
31. Burke, R.E. (2007) Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: Two approaches with therapeutic potential in the treatment of neurodegenerative disease. Pharmacol. Ther., 114, 261-277.
32. Humbert, S., Bryson, E.A., Cordelières, F.P., Connors, N.C., Datta, S.R., Finkbeiner, S., Greenberg, M.E. and Saudou, F. (2002) The IGF-1/Akt Pathway Is Neuroprotective in Huntington's Disease and Involves Huntingtin Phosphorylation by Akt. Dev. Cell, 2, 831-837.
33. Pardo, R., Colin, E., Régulier, E., Aebischer, P., Déglon, N., Humbert, S. and Saudou, F. (2006) Inhibition of calcineurin by FK506 protects against polyglutamine-huntingtin toxicity through an increase of huntingtin phosphorylation at S421. J. Neurosci., 26, 1635-1645.
34. Wellington, C.L., Ellerby, L.M., Gutekunst, C.A., Rogers, D., Warby, S., Graham, R.K., Loubser, O., van Raamsdonk, J., Singaraja, R., Yang, Y.Z., et al. (2002) Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J. Neurosci., 22, 7862-7872.
35. Colin, E., Régulier, E., Perrin, V., Dürr, A., Brice, A., Aebischer, P., Déglon, N., Humbert, S. and Saudou, F. (2005) Akt is altered in an animal model of Huntington's disease and in patients. Eur. J. Neurosci., 21, 1478-1488.
36. Freeman, A.Y., Soghomonian, J.J. and Pierce, R.C. (2003) Tyrosine kinase B and C receptors in the neostriatum and nucleus accumbens are co-localized in enkephalinpositive and enkephalin-negative neuronal profiles and their expression is influenced by cocaine. Neuroscience, 117, 147-156.
37. Metz, R. and Ziff, E. (1991) cAMP stimulates the C/EBP-related transcription factor rNFIL-6 to trans-locate to the nucleus and induce c-fos transcription. Genes Dev., 5, 1754-1766.
38. Russell, D.L., Doyle, K.M.H., Gonzales-Robayna, I., Pipaon, C. and Richards, J.S. (2003) Egr-1 induction in rat granulosa cells by follicle-stimulating hormone and luteinizing hormone: combinatorial regulation by transcription factors cyclic adenosine 3', 5'-monophosphate regulatory element binding protein, serum response factor, sp1, and early growth response factor-1. Mol. Endocrinol., 17, 520-533.
39. Chen, Y. and Hughes-Fulford, M. (2000) Prostaglandin E2 and the protein kinase A pathway mediate arachidonic acid induction of c-fos in human prostate cancer cells. Br. J. Cancer, 82, 2000-2006.
40. Hervé, D., Lévi-Strauss, M., Marey-Semper, I., Verney, C., Tassin, J.P., Glowinski, J. and Girault, J.A. (1993) G(olf) and Gs in rat basal ganglia: possible involvement of G(olf) in the coupling of dopamine D1 receptor with adenylyl cyclase. J. Neurosci., 13, 2237-2248.
41. Corvol, J.C., Studler, J.M., Schonn, J.S., Girault, J.A. and Hervé, D. (2001) Galpha(olf) is necessary for coupling D1 and A2a receptors to adenylyl cyclase in the striatum. J. Neurochem., 76, 1585-1588.
42. Miyamoto, E., Kuo, J.F. and Greengard, P. (1968) Adenosine 3', 5'-monophosphate-dependent protein kinase from brain. Science, 165, 63-65.
43. Rangone, H., Poizat, G., Troncoso, J., Ross, C.A., MacDonald, M.E., Saudou, F. and Humbert, S. (2004) The serum-and glucocorticoid-induced kinase SGK inhibits mutant huntingtin-induced toxicity by phosphorylating serine 421 of huntingtin. Eur. J. Neurosci., 19, 273-279.
44. Skuza, G., Szymánska, M., Budziszewska, B., Abate, C. and Berardi, F. (2011) Effects of PB190 and PB212, new r receptor ligands, on glucocorticoid receptor-mediated gene transcription in LMCAT cells. Pharmacol. Rep., 63, 1564-1568.
45. Atwal, J.K., Massie, B., Miller, F.D. and Kaplan, D.R. (2000) The TrkB-Shc site signals neuronal survival and local axon growth via MEK and P13-kinase. Neuron, 27, 265-277.
46. Dijkhuizen, P.A. and Ghosh, A. (2005) BDNF regulates primary dendrite formation in cortical neurons via the PI3-kinase and MAP kinase signaling pathways. J. Neurobiol., 62, 278-288.
47. Wang, H.Y., Stucky, A., Hahn, C.G., Wilson, R., Bennett, D. and Arnold, S. (2011) BDNF-trkB signaling in late life cognitive decline and Alzheimer's disease. Transl. Neurosci., 2, 91-100.
48. Brami-Cherrier, K., Valjent, E., Garcia, M., Pagès, C., Hipskind, R.A. and Caboche, J. (2002) Dopamine induces a PI3-kinase-independent activation of Akt in striatal neurons: a new route to cAMP response element-binding protein phosphorylation. J. Neurosci., 22, 8911-8921.
49. Emamian, E.S., Hall, D., Birnbaum, M.J., Karayiorgou, M. and Gogos, J.A. (2004) Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat. Genet., 36, 131-137.
50. Beaulieu, J.M., Sotnikova, T.D., Yao, W.D., Kockeritz, L., Woodgett, J.R., Gainetdinov, R.R. and Caron, M.G. (2004) Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc. Natl. Acad. Sci. U.S.A, 101, 5099-5104.
51. Kalinichev, M. and Dawson, L.A. (2011) Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK3) inhibitors in a strain-specific model of acute mania. Int. J. Neuropsychopharmacol., 14, 1051-1067.
52. Beaulieu, J.M. and Gainetdinov, R.R. (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev., 63, 182-217.
53. Numakawa, T., Kumamaru, E., Adachi, N., Yagasaki, Y., Izumi, A. and Kunugi, H. (2009) Glucocorticoid receptor interaction with TrkB promotes BDNF-triggered PLC-signaling for glutamate release via a glutamate transporter. Proc. Nat. Acad. Sci., 106, 647-652.
54. Jeanneteau, F., Garabedian, M.J. and Chao, M.V. (2008) Activation of Trk neurotrophin receptors by glucocorticoids provides a neuroprotective effect. Proc. Nat. Acad. Sci., 105, 4862-4867.
55. Liévens, J.C., Iché, M., Laval, M., Faivre-Sarrailh, C. and Birman, S. (2008) AKT-sensitive or insensitive pathways of toxicity in glial cells and neurons in Drosophila models of Huntington's disease. Hum. Mol. Genet., 17, 882-894.
56. Chen, D.Y., Bambah-Mukku, D., Pollonini, G. and Alberini, C.M. (2012) Glucocorticoid receptors recruit the CaMKIIa-BDNF-CREB pathways to mediate memory consolidation. Nat. Neurosci., 15, 1707-1714.
57. Urani, A., Roman, F.J., Phan, V.L., Su, T.P. and Maurice, T. (2001) The antidepressant-like effect induced by sigma(1)-receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J. Pharmacol. Exp. Ther., 298, 1269-1279.
58. Maurice, T., Su, T.P. and Privat, A. (1998) Sigma1 (r1) receptor agonists and neurosteroids attenuate b25-35-amyloid peptide-induced amnesia in mice through a common mechanism. Neuroscience, 83, 413-428.